Biomarkers and targets for cancer immunotherapy
OwnerLaszlo RADVANYI, Jie Qing CHEN +1inventors
InventorsLaszlo RADVANYI, Jie Qing CHEN, Patrick HWU
Life of this patent
Estimating the term…
Abstract
Provided herein are predictive biomarker signatures that identify patients as likely to benefit from TIL therapy. Also provided are tumor immunotherapy resistance pathways that may be targets of combination therapies to enhance TIL therapy.
Claims50
A method of treating a patient having cancer comprising administering an effective amount of an anti-cancer immunotherapy to the patient, said patient having been determined to have a cancer comprising an elevated expression level of LTF compared to a reference expression level and/or a decreased expression level of IRAK-1 compared to a reference expression level.
A method of treating a patient having cancer comprising administering an effective amount of autologous tumor-infiltrating lymphocytes to the patient, said patient having been determined to have a cancer comprising an elevated expression level of LTF compared to a reference expression level and/or a decreased expression level of IRAK-1 compared to a reference expression level.
A method of treating a cancer patient comprising administering an effective amount of an anti-LTF therapy in combination with an immunotherapy to the patient, said patient having been determined to have a cancer comprising an elevated expression level of LTF compared to a reference expression level.
A method of identifying a cancer patient as a candidate for an anti-cancer immunotherapy comprising determining an expression level of LTF and/or IRAK-1 in the cancer, wherein an increased expression level of LTF compared to a reference expression level and/or a decreased expression level of IRAK-1 compared to a reference expression level is indicative of the cancer patient being a candidate for autologous TIL therapy.
A method of identifying a cancer patient as a candidate for autologous TIL therapy comprising determining an expression level of LTF and/or IRAK-1 in the cancer, wherein an increased expression level of LTF compared to a reference expression level and/or a decreased expression level of IRAK-1 compared to a reference expression level is indicative of the cancer patient being a candidate for autologous TIL therapy.
A method of characterizing a cancer comprising selectively testing a cancer sample to determine the level of expression of LTF and/or IRAK-1.
Dependencies are inferred from the claim text.